Aripiprazole: Nursing Drug Guide, Akathisia & NCLEX Review
Healthcare medication guide: recognize akathisia and extrapyramidal red flags early, apply boxed-warning monitoring for dementia-related psychosis and antidepressant-adjunct suicidality, and escalate NMS without mistaking motor restlessness for psychiatric decompensation.
Aripiprazole can cause akathisia (subjective inner restlessness with objective pacing or fidgeting)—about twice the placebo rate in adult schizophrenia trials and the most common dose-related extrapyramidal complaint. Do not mistake akathisia for worsening psychosis or anxiety alone. Also monitor for other extrapyramidal symptoms (EPS) and rare but life-threatening neuroleptic malignant syndrome (NMS) (hyperpyrexia, rigidity, altered mental status, autonomic instability). Boxed warnings: increased mortality in elderly patients with dementia-related psychosis (not approved for this use) and increased suicidal thoughts and behaviors when used as antidepressant adjunct—especially in young adults. Screen mood and safety at initiation and after every dose change.
📋 Contents
⚡ Quick facts
💡 Key takeaway
When a patient on aripiprazole cannot sit still, paces the unit, or describes unbearable inner restlessness—especially within days of a dose increase—assess for akathisia before assuming psychiatric decompensation. Document objective motor restlessness, notify the prescriber or pharmacist, and watch for NMS if fever, rigidity, or altered mental status appear.
Most common brand names
Aripiprazole is available as tablets, orally disintegrating tablets, oral solution, and long-acting injectable products. Verify the specific formulation on the MAR—dose units and titration differ between oral and depot preparations.
Common U.S. brands include Abilify (oral), Abilify Maintena and Aristada (long-acting injectable), and Abilify Mycite (tablet with sensor). Generic aripiprazole is widely used in inpatient and outpatient settings.
Why we give it — Indications
Per current U.S. prescribing information, aripiprazole is indicated for schizophrenia, acute manic/mixed episodes of bipolar I disorder (monotherapy or adjunct to lithium/valproate), adjunctive treatment of major depressive disorder (MDD) when antidepressant alone is inadequate, irritability associated with autistic disorder (pediatric), and Tourette disorder (pediatric). It is not approved for dementia-related psychosis.
| Use | Detail |
|---|---|
| Schizophrenia | Adults and adolescents 13–17 years; maintenance after stabilization on other antipsychotics per labeling |
| Bipolar I — mania/mixed | Adults and pediatric patients 10–17 years with bipolar disorder; monotherapy or adjunct to lithium or valproate |
| Major depressive disorder (adjunct) | Adjunct to antidepressants in adults with depression not responding to antidepressant alone; monitor for suicidality per boxed warning |
| Autistic disorder irritability | Pediatric patients 6–17 years |
| Tourette disorder | Pediatric patients 6–18 years |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Aripiprazole is an atypical antipsychotic with a unique pharmacologic profile: partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at 5-HT2A receptors. This partial D2 activity may contribute to lower prolactin elevation than some antipsychotics, but EPS and akathisia still occur—nurses cannot assume “atypical” means absent motor side effects.
Dosing overview
Verify every order against current prescribing information, renal/hepatic status, CYP2D6 metabolizer status, and interacting drugs. Dose increases should generally not be made before 2 weeks in schizophrenia maintenance contexts; adjunct MDD and other indications specify minimum one-week intervals between adjustments.
| Scenario | Dose adjustment (labeling) |
|---|---|
| Known CYP2D6 poor metabolizers | Administer half of usual dose |
| Strong CYP2D6 or CYP3A4 inhibitors | Administer half of usual dose (e.g., fluoxetine, paroxetine, itraconazole) |
| Strong CYP2D6 and CYP3A4 inhibitors | Administer one-quarter of usual dose |
| Strong CYP3A4 inducers | Double usual dose over 1–2 weeks (e.g., carbamazepine, rifampin) |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Take as soon as remembered unless near next dose; do not double doses. For long-acting injectable products, follow missed-dose labeling and contact prescriber/pharmacy—do not self-administer depot doses outside protocol.
Before you give it — Safety check
Pretreatment checks
- Confirm indication is not dementia-related psychosis (boxed warning— increased mortality; not approved)
- Perform medication reconciliation for antidepressant adjunct plans, benzodiazepines, and CYP inhibitors/inducers
- Baseline weight, waist circumference if protocol requires; plan fasting glucose and lipids per metabolic monitoring guidance
- Assess fall risk, orthostatic vitals, swallowing, and history of EPS, NMS, or seizure disorder
Contraindications
- Known hypersensitivity to aripiprazole (reactions have ranged from pruritus/urticaria to anaphylaxis)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) | Increased aripiprazole levels—requires dose reduction per labeling | Hold or verify adjusted dose with pharmacy before administration; monitor for sedation and EPS |
| Strong CYP3A4 inducers (carbamazepine, rifampin) | Decreased aripiprazole levels—may need dose doubling over 1–2 weeks | Notify prescriber/pharmacist if inducer started or stopped; watch for relapse if levels fall |
| Benzodiazepines (e.g., lorazepam) | Greater sedation and orthostatic hypotension than either drug alone in labeling | Monitor blood pressure, sedation, and fall risk; adjust per prescriber |
| Antidepressants (e.g., sertraline) | MDD adjunct carries boxed warning for suicidality; akathisia rates higher than placebo in trials | Screen mood and safety at visits; distinguish akathisia from agitation due to depression |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets and solution: May be given without regard to meals per labeling. Use the calibrated device for oral solution—do not use household spoons.
- Orally disintegrating tablets: peel blister, place on tongue to dissolve; do not push through foil; swallow with or without liquid
- Long-acting injectable products (Abilify Maintena, Aristada): administer only by trained personnel per institutional protocol and product labeling—never substitute oral mg for depot mg
Some formulations are not interchangeable. Confirm with pharmacy before crushing, splitting, or giving via enteral tube.
Expected therapeutic response
- Gradual improvement in target symptoms (psychosis, mania, irritability, tics) over days to weeks—not immediate like benzodiazepines
- Improved sleep or reduced agitation in some patients, but new restlessness may signal akathisia rather than success
- Stable vital signs without fever, rigidity, or escalating EPS on serial nursing assessment
Red flags — Stop and act
Escalate immediately for NMS, severe EPS, suicidality, or cerebrovascular events in vulnerable patients.
- Akathisia: subjective inner restlessness with pacing, leg swinging, or inability to remain seated—especially after dose increases; adult schizophrenia trials reported akathisia in 8% vs 4% placebo
- NMS: hyperpyrexia, muscle rigidity, confusion or altered mental status, tachycardia, labile blood pressure, diaphoresis—hold antipsychotic and activate emergency pathway
- New or worsening suicidal ideation, self-harm, or violent impulses when used as antidepressant adjunct—especially young adults
- Signs of cerebrovascular adverse events in elderly patients (e.g., stroke, transient ischemic attack)—labeling reports increased events in dementia-related psychosis trials
- Severe hypersensitivity, angioedema, or difficulty breathing after dose
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Akathisia | Common in schizophrenia (8% vs 4% placebo); up to 25% as MDD adjunct in trials | Assess motor restlessness; notify prescriber; avoid mislabeling as anxiety only |
| Tremor, extrapyramidal disorder | Common across indications; higher in pediatrics | Document EPS scales if used; hold and notify for severe rigidity or dysphagia |
| Nausea, insomnia, headache | ≥10% in pooled adult trials | Supportive care; differentiate insomnia from akathisia-related restlessness |
| Somnolence / sedation | Adults 11% vs 6% placebo; higher in children | Fall precautions; avoid sedative stacking with benzodiazepines |
| Metabolic changes | Hyperglycemia, dyslipidemia, weight gain class effect | Monitor glucose and lipids; teach polydipsia/polyuria symptoms |
| Orthostatic hypotension / syncope | Orthostatic hypotension ~1%; syncope ~0.5% adults | Orthostatic vitals; slow position changes; fall risk assessment |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Prescribing information states no specific antidote for aripiprazole overdosage. Management is supportive: airway, breathing, circulation, cardiac monitoring, and treatment of severe EPS or NMS per institutional protocol.
Early signs
- Somnolence, vomiting, tremor, akathisia, hypotension, or tachycardia
- Single overdoses up to 1260 mg in adults have been reported with recovery; fatalities reported mainly in combination overdoses
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose—especially with co-ingestants or altered mental status.
Hemodialysis is unlikely to be useful because aripiprazole is highly protein bound.
Look-alike / sound-alike and error prevention
- Aripiprazole vs risperidone, quetiapine, olanzapine—verify generic name on MAR; different EPS and metabolic profiles
- Oral mg vs long-acting injectable—never use oral tablet dose for depot products
- Abilify vs other “A” antipsychotics in automated dispensing—scan barcode and confirm patient identity
- Multiple daily strengths on cart—independent double-check when 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg tablets stocked together
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Akathisia screen | Ask about inner restlessness; observe pacing in hallway or chair rocking; use facility EPS/akathisia scale if available |
| Food timing | Oral doses may be given without regard to meals |
| Enteral tube | Confirm formulation with pharmacy—some tablets may not be crushable |
| Lab timing | Fasting glucose at baseline and periodically; lipids per protocol; CBC if clinical signs of infection or neutropenia |
| Commonly missed | Attributing pacing to “anxiety” or “bipolar mania” without EPS assessment after dose changes |
| Ask pharmacy when | New CYP inhibitor/inducer, poor metabolizer status, or need for dose halving/quartering |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Elderly with dementia-related psychosis | Not approved; boxed warning of increased mortality with antipsychotics in this population; monitor for somnolence, dysphagia, aspiration, and cerebrovascular events if used off-label |
| Older adults (general) | Greater sensitivity to orthostatic hypotension, sedation, and falls; use dementia-appropriate alternatives when possible |
| Diabetes / metabolic risk | Screen for type 2 diabetes risk factors; monitor fasting glucose and symptoms of hyperglycemia |
| Pediatrics and adolescents | Higher rates of somnolence and EPS in trials; MDD adjunct not approved in pediatrics per labeling |
| Seizure history | Antipsychotics may lower seizure threshold—use caution in epilepsy |
| Pregnancy / lactation | Third-trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates—monitor neonates per labeling; consult specialist for risk/benefit |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Akathisia and EPS (observe gait, pacing, rigidity, tremor) especially first weeks and after titration
- Mood, behavior, and suicidal ideation when used as antidepressant adjunct—daily observation per labeling
- Fasting glucose and symptoms of hyperglycemia; blood glucose monitoring per protocol
- Lipid panel, weight/BMI, and waist circumference at baseline and periodically
- Orthostatic blood pressure and heart rate; sedation level
Document
- Dose, route, time, and any dose change linked to EPS assessment
- Objective description of motor restlessness (not only “agitated”) and prescriber/pharmacist notifications
- Metabolic labs obtained and patient teaching on diabetes symptoms
Patient teaching
- Report inability to sit still, pacing, or inner restlessness that feels unbearable—these may be akathisia and need a medication review, not “toughing it out”
- Do not stop abruptly without prescriber guidance; report fever, stiff muscles, confusion, or fast heartbeat immediately
- When used with antidepressants, report worsening mood, suicidal thoughts, or unusual behavior changes—especially early in therapy
- Watch for increased thirst, urination, or hunger—possible hyperglycemia; attend scheduled lab appointments
- Rise slowly from sitting or lying down to prevent dizziness or falls
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Known hypersensitivity to aripiprazole
- Suspected NMS (fever, rigidity, altered mental status, autonomic instability)
- Severe extrapyramidal toxicity or uncontrolled akathisia after recent dose increase
- New suicidal ideation, self-harm behavior, or violent impulses (especially on antidepressant adjunct)
- Significant orthostatic hypotension, syncope, or prescriber hold for cerebrovascular event
- Order exceeds labeled maximum (30 mg/day oral) without documented rationale
- Strong CYP3A4 or CYP2D6 inhibitor or inducer newly added without accompanying dose adjustment plan
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Aripiprazole’s partial dopamine activity does not eliminate motor toxicity. Build akathisia screening into every medication pass during the first 2–4 weeks and after each titration—especially on psychiatric units and when augmenting antidepressants.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right formulation (oral vs depot)
- Review new interacting drugs and whether pharmacy adjusted dose for CYP inhibitors/inducers
- Observe patient ambulation before and after dose when possible—pacing clusters may be visible in hallways
2. High-alert and safety badge
Not universally listed as high-alert, but carries boxed warnings and EPS/NMS riskTreat dose changes like high-risk antipsychotic titrations: reassess EPS and mood within the same shift when feasible.
3. Clinical workflow: hold and question rules
- If patient cannot remain seated and distress is escalating after a dose increase, hold next dose and request prescriber/pharmacist review for akathisia management
- If fever and rigidity appear, hold antipsychotic and initiate NMS pathway—do not attribute solely to infection without assessment
- For MDD adjunct, pair medication administration with brief mood/safety check and family caregiver alert per policy
4. Critical teach-back questions
- “What feelings or movements should you report right away?” (Inner restlessness, pacing, fever with stiff muscles, suicidal thoughts.)
- “What will you do if you miss a dose?” (Take when remembered unless close to next dose; do not double; call clinic for depot missed doses.)
5. Care coordination
Pharmacist: CYP-mediated dose adjustments, drug interaction checks, and akathisia treatment options (dose reduction, beta-blocker, anticholinergic per prescriber)
Prescriber / psychiatry: EPS management, suicidality, metabolic monitoring, and alternative antipsychotic selection
🧠 Quick mental checklist
- Is this restlessness akathisia (motor) or mood worsening (psychiatric)?
- Did akathisia start or worsen after a recent dose increase?
- Any fever, rigidity, tachycardia, or confusion suggesting NMS?
- For MDD adjunct: any new suicidal thoughts or self-harm statements?
- Are glucose, weight, and lipids tracked per atypical antipsychotic protocol?
Aripiprazole NCLEX practice questions
Practice NCLEX-style clinical judgment practice for aripiprazole using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, documentation cloze, antidepressant-adjunct safety, and matrix urgency for akathisia versus NMS—recognize cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Aripiprazole 10 mg PO daily — increased to 15 mg PO daily 48 hours ago
- Sertraline 100 mg PO daily (MDD adjunct regimen)
- Lorazepam 0.5 mg PO q6h PRN anxiety — given once in last 24 h
- Next aripiprazole dose due 2000
- Admission: fasting glucose 98 mg/dL; HbA1c 5.6%
- Today: fasting glucose 112 mg/dL (repeat ordered)
- Lipids: total cholesterol 198 mg/dL; triglycerides 142 mg/dL (baseline)
- CK 180 U/L (within facility reference)
- 0800: T 36.8 °C, HR 88, BP 118/72, RR 16, SpO2 98% on room air
- 1400: T 36.9 °C, HR 102, BP 124/78, RR 18 — patient pacing hallway
- 1800: T 39.1 °C, HR 124, BP 98/60, RR 22, SpO2 97% — reported in separate NMS drill note
- 28-year-old with MDD on sertraline; aripiprazole added 2 weeks ago, dose increased 48 h ago
- 1400: “I feel like I need to crawl out of my skin.” Observed pacing and leg bouncing; mood otherwise stable; denies suicidal plan
- 1800 (different scenario for matrix): rigidity noted on passive ROM; confused to place; diaphoresis
Answer key & rationale
Frequently asked questions
What should nurses monitor most closely when starting aripiprazole?
Assess for akathisia and other extrapyramidal symptoms, especially during the first weeks and after dose increases. Monitor mood and behavior for worsening depression or suicidality when aripiprazole is used as antidepressant adjunct in young adults. Track weight, fasting glucose, and lipids per atypical antipsychotic labeling. In older adults, screen for orthostatic hypotension, falls, somnolence, and swallowing difficulty.
When should a nurse hold aripiprazole and contact the prescriber or pharmacist?
Hold for known hypersensitivity, suspected neuroleptic malignant syndrome, severe extrapyramidal toxicity, new suicidal ideation or self-harm behavior, significant orthostatic hypotension or syncope, or orders that exceed labeled maximum daily dose without documented rationale. Also hold when strong CYP3A4 or CYP2D6 inhibitors or inducers are newly added without an accompanying dose adjustment plan.
How does akathisia from aripiprazole present at the bedside?
Akathisia is subjective inner restlessness with objective pacing, fidgeting, or inability to remain seated. In adult schizophrenia trials it occurred at about twice the placebo rate and was the most common dose-related extrapyramidal complaint. Patients may describe anxiety or insomnia, but the key cue is motor restlessness that distresses the patient and may be mistaken for worsening psychiatric symptoms.
Is there a specific antidote for aripiprazole overdose?
Prescribing information states no specific overdose treatment exists. Management is supportive: airway, breathing, circulation, cardiac monitoring if QT prolongation is present, and symptom-directed care. Activated charcoal may reduce absorption if given early. Hemodialysis is unlikely to be useful because aripiprazole is highly protein bound.
Can aripiprazole be used for dementia-related psychosis?
No. Aripiprazole carries a boxed warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs have increased mortality, and aripiprazole is not approved for dementia-related psychosis. If used off-label, labeling requires assessment for excessive somnolence or dysphagia that could predispose to aspiration.
References
-
U.S. National Library of Medicine. ARIPIPRAZOLE tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85cc7d25-414b-4b6f-a03a-48af908a16a1
-
U.S. Food and Drug Administration. Medication Guide: What is the most important information I should know about aripiprazole?https://www.fda.gov/media/77255/download
-
National Library of Medicine. MedlinePlus: Aripiprazole.https://medlineplus.gov/druginfo/meds/a603012.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.